Patents matching “ONC”

US 7749532

Once daily formulations of tetracyclines

Supernus Pharmaceuticals, Inc. · Granted Jul 6, 2010 · Expires Jul 1, 2030

US 7731951

Viruses for the treatment of cellular proliferative disorders

ONCOLYTICS BIOTECH INC. · Granted Jun 8, 2010 · Expires Jun 3, 2030

US 7727534

Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions

ONCOLYTICS BIOTECH INC. · Granted Jun 1, 2010 · Expires May 27, 2030

US 7708987

Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders

ONCOLYTICS BIOTECH INC. · Granted May 4, 2010 · Expires Apr 29, 2030

US 7638550

Pyrrolic derivatives with histone deacetylase inhibitory activity

Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV-EHU) Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO) · Granted Dec 29, 2009 · Expires Dec 24, 2029

US 7608257

Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus

ONCOLYTICS BIOTECH INC. · Granted Oct 27, 2009 · Expires Oct 22, 2029

US 7604944

Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same

Theravance, Inc. · Granted Oct 20, 2009 · Expires Oct 15, 2029

US 7585653

Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same

Theravance, Inc. · Granted Sep 8, 2009 · Expires Sep 3, 2029

US 7582289

Viruses for the treatment of cellular proliferative disorders

ONCOLYTICS BIOTECH INC. · Granted Sep 1, 2009 · Expires Aug 27, 2029

US 7576065

Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein

REGENERON PHARMACEUTICALS, INC. · Granted Aug 18, 2009 · Expires Aug 13, 2029

US 7476382

Reovirus for the treatment of neoplasia

ONCOLYTICS BIOTECH INC. · Granted Jan 13, 2009 · Expires Jan 8, 2029

US 7468426

Oncoprotein protein kinase antibody kit

The Regents of the University of California · Granted Dec 23, 2008 · Expires Dec 18, 2028

US 7452723

Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders

ONCOLYTICS BIOTECH INC. · Granted Nov 18, 2008 · Expires Nov 13, 2028

US 7431932

Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions

ONCOLYTICS BIOTECH INC. · Granted Oct 7, 2008 · Expires Oct 2, 2028

US 7429485

Method of producing infectious reovirus

ONCOLYTICS BIOTECH INC. · Granted Sep 30, 2008 · Expires Sep 25, 2028

US 7410978

Once daily dosage forms of trospium

Supernus Pharmaceuticals, Inc. · Granted Aug 12, 2008 · Expires Aug 7, 2028

US 7374752

Reovirus for the treatment of cellular proliferative disorders

ONCOLYTICS BIOTECH INC. · Granted May 20, 2008 · Expires May 15, 2028

US 7358226

Ultrasonic concentration of drug delivery capsules

The Regents of the University of California · Granted Apr 15, 2008 · Expires Apr 10, 2028

US 7344711

Use of adenoviruses mutated in the VA genes for cancer treatment

ONCOLYTICS BIOTECH INC. · Granted Mar 18, 2008 · Expires Mar 13, 2028

US 7330748

Method for determining in vivo concentration of a metabolite

The United States of America, as represented by the Department of Health and Human Services · Granted Feb 12, 2008 · Expires Feb 7, 2028

WO 2007147454

SYNTHÈSE CHIMIQUE DE LA CU-64ASP (CUIVRE-64ASPARAGINASE ; [64CU]ASPARARAGINASE) POUR PET SCAN ET RADIOTHÉRAPIE

A C O M ADVANCED CT ONCOLOGY M [IT] · Granted Dec 27, 2007 · Expires Dec 22, 2027

US 7300650

Reovirus for the treatment of neoplasia

ONCOLYTICS BIOTECH INC. · Granted Nov 27, 2007 · Expires Nov 22, 2027

US 7264798

Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus

ONCOLYTICS BIOTECH INC. · Granted Sep 4, 2007 · Expires Aug 30, 2027

US 7252817

Viruses for the treatment of cellular proliferative disorders

ONCOLYTICS BIOTECH INC. · Granted Aug 7, 2007 · Expires Aug 2, 2027